Table 2 All-cause post-tuberculosis mortality rates among persons who initiated treatment for RR or M/XDR TB with and without pre-existing comorbidities in Georgia, 2009–2017 (N = 998)a.

From: HIV co-infection increases the risk of post-tuberculosis mortality among persons who initiated treatment for drug-resistant tuberculosis

Characteristics

All-cause mortality post-tuberculosis treatment

 

Death/total (%)

Person time (years)

Crude rates (95%CI)

per 1000 person-years

Rate difference (95%CI)

per 1000 person years

Median time to death post-TB treatment, months (IQR)

Median age at time of death, years (IQR)

All cohort

87/998 (8.7)

4857

17.91 (14.43–21.99)

 

21 (7–39)

50 (39–63)

HIV co-infection

 No

68/878 (7.7)

4195

16.12 (12.78–20.56)

Reference

22 (7–39)

53 (37–64)

 Yes

9/32 (28.1)

130

69.23 (36.02–133.10)

53.02 (7.63, 98.41)

7 (4–9)

41 (39–46)

 Missing

10/88 (11.4)

532

18.80 (10.11–34.94)

2.59 (− 9.68, 14.86)

23 (13–46)

50 (43–59)

Hyperglycemiab

 No

41/558 (7.4)

2712

15.12 (11.13–20.53)

Reference

28 (9–43)

50 (39–63)

 Yes

27/231 (11.7)

1129

23.91 (16.40–34.87)

8.80 (− 1.34, 18.93)

19 (7–34)

59 (38–66)

 Missing

19/209 (9.1)

1016

18.70 (11.93–29.32)

3.58 (− 6.02, 13.18)

21 (6–40)

46 (36–56)

Diabetes status

 No diabetes

41/558 (7.4)

2712

15.12 (11.13–20.53)

Reference

28 (9–43)

50 (39–63)

 Pre-diabetes

13/119 (10.9)

593

21.92 (12.73–37.75)

6.80 (− 5.98, 19.59)

17 (7–31)

48 (35–59)

 Diabetes

14/112 (12.5)

536

26.12 (15.47–44.10)

11.00 (− 3.44, 25.44)

22 (10–38)

63 (49–68)

 Missing

19/209 (9.1)

1016

18.70 (11.93–29.32)

3.58 (− 6.02, 13.18)

21 (6–40)

46 (36–56)

HCV co-infection

 No

46/580 (7.9)

2872

16.02 (12.00–21.38)

Reference

20 (9–39)

50 (38–63)

 Yes

18/147 (12.2)

701

25.68 (16.18–40.76)

9.66 (− 3.07, 2.24)

20 (8–38)

57 (39–62)

 Missing

23/271 (8.5)

1284

17.91 (11.90–26.96)

1.90 (− 6.77, 10.56)

22 (6–45)

49 (41–64)

Any primary comorbidityc

 No

41/641 (6.4)

3128

13.11 (9.65–17.80)

Reference

28 (13–41)

49 (38–59)

 Yes

/357 (12.9)

1729

26.60 (19.93–35.52)

13.50 (4.83–22.17)

19 (6–38)

54 (39–64)

  1. CI: confidence interval; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IQR: interquartile range; TB: tuberculosis.
  2. Bold indicates that the finding is statistically significant at α = 0.05.
  3. a34 individuals who died during treatment were excluded from the post-TB mortality analyses.
  4. bIncluded individuals with pre-diabetes and diabetes.
  5. cAny primary comorbidity was defined as the presence of either HIV co-infection, diabetes/hyperglycemia, or HCV co-infection. These included 188 individuals with hyperglycemia only, 18 individuals with HIV co-infection only, 100 individuals with HCV co-infection only, 4 individuals with hyperglycemia and HIV co-infection, 37 individuals with hyperglycemia and HCV co-infection, 8 individuals with HIV and HCV co-infections, and 2 individuals with hyperglycemia, HIV and HCV co-infections.
Back to article page